These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37450983)

  • 1. [Dalbavancin is an antimicrobial to consider in prosthetic orthopedic infections caused by Staphylococcus].
    Sánchez Ortiz M; Linge Martín M; González Eizaguirre MM
    Rev Esp Geriatr Gerontol; 2023; 58(5):101378. PubMed ID: 37450983
    [No Abstract]   [Full Text] [Related]  

  • 2.
    Plota M; Papadimitriou-Olivgeris M; Kolonitsiou F; Tsiata E; Spiliopoulou I; Assimakopoulos SF; Marangos M
    J Med Microbiol; 2021 Sep; 70(9):. PubMed ID: 34559042
    [No Abstract]   [Full Text] [Related]  

  • 3. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.
    Steele JM; Seabury RW; Hale CM; Mogle BT
    J Clin Pharm Ther; 2018 Feb; 43(1):101-103. PubMed ID: 28628223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
    Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
    Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated With Dalbavancin: Case Report and Isolate Characterization.
    Zhang R; Polenakovik H; Barreras Beltran IA; Waalkes A; Salipante SJ; Xu L; Werth BJ
    Clin Infect Dis; 2022 Oct; 75(9):1641-1644. PubMed ID: 35510938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging resistance in Staphylococcus epidermidis during dalbavancin exposure: a case report and in vitro analysis of isolates from prosthetic joint infections.
    Al Janabi J; Tevell S; Sieber RN; Stegger M; Söderquist B
    J Antimicrob Chemother; 2023 Mar; 78(3):669-677. PubMed ID: 36611258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro time-kill kinetics of dalbavancin against Staphylococcus spp. biofilms over prolonged exposure times.
    Di Pilato V; Ceccherini F; Sennati S; D'Agostino F; Arena F; D'Atanasio N; Di Giorgio FP; Tongiani S; Pallecchi L; Rossolini GM
    Diagn Microbiol Infect Dis; 2020 Feb; 96(2):114901. PubMed ID: 31761480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections.
    Fernández J; Greenwood-Quaintance KE; Patel R
    Diagn Microbiol Infect Dis; 2016 Aug; 85(4):449-51. PubMed ID: 27241369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dalbavancin combined with linezolid in prosthetic-hip infection.
    Carrión Madroñal IM; Sánchez Del Moral R; Abad Zamora JM; Martínez Marcos FJ
    Rev Esp Quimioter; 2020 Apr; 33(2):147-148. PubMed ID: 32157859
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions.
    Johnson DM; Fritsche TR; Sader HS; Jones RN
    Int J Antimicrob Agents; 2006 Jun; 27(6):557-60. PubMed ID: 16698238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):177-84. PubMed ID: 19249179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prolonged treatment with dalbavancin in prosthetic hip infection by methicillin-resistant Staphylococcus epidermidis].
    Trujillano Ruiz A; Mesquida Riera J; Serrano Fabiá MA; Riera Pérez E; Mejía Benard A; Taberner Ferrer MD
    Rev Esp Quimioter; 2019 Apr; 32(2):203-204. PubMed ID: 30868837
    [No Abstract]   [Full Text] [Related]  

  • 13. Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres.
    Sader HS; Mendes RE; Pfaller MA; Flamm RK
    J Antimicrob Chemother; 2019 May; 74(5):1306-1310. PubMed ID: 30753485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-biofilm activity of dalbavancin against methicillin-resistant
    Silva V; Miranda C; Bezerra M; Antão HS; Guimarães J; Prada J; Pires I; Maltez L; Pereira JE; Capelo JL; Igrejas G; Poeta P
    J Chemother; 2021 Nov; 33(7):469-475. PubMed ID: 33904369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Extracellular DNA in Dalbavancin Activity against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms in Patients with Skin and Soft Tissue Infections.
    Sivori F; Cavallo I; Kovacs D; Guembe M; Sperduti I; Truglio M; Pasqua M; Prignano G; Mastrofrancesco A; Toma L; Pimpinelli F; Morrone A; Ensoli F; Di Domenico EG
    Microbiol Spectr; 2022 Apr; 10(2):e0035122. PubMed ID: 35416701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of dalbavancin in a rat model of methicillin-resistant Staphylococcus aureus (MRSA)-osteomyelitis.
    Silva V; Miranda C; Antão HS; Guimarães J; Prada J; Pires I; Maltez L; Pereira JE; Capelo JL; Igrejas G; Poeta P
    Int J Antimicrob Agents; 2020 Jul; 56(1):106021. PubMed ID: 32439480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New antimicrobial agents for methicillin-resistant Staphylococcus aureus.
    Kollef MH
    Crit Care Resusc; 2009 Dec; 11(4):282-6. PubMed ID: 20001879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
    Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model.
    Jabés D; Candiani G; Romanó G; Brunati C; Riva S; Cavaleri M
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1118-23. PubMed ID: 15047510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018-2020).
    Sader HS; Castanheira M; Huband MD; Shortridge D; Carvalhaes CG; Mendes RM
    Eur J Clin Microbiol Infect Dis; 2022 May; 41(5):867-873. PubMed ID: 35355158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.